Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...
Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
Backed by a $2.9 million R01 grant from the National Institutes of Health, Barrow Neurological Institute researchers are expanding their efforts to test a hypothesis that exposure to environmental ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...